Ocuphire reports Q1 2023 cash $39M; Nyxol PDUFA Sept 28; net loss $5.8M

Opus Genetics, Inc.

2023-Q1 EPS reported -$0.28 revenue$1,749,000

Cash and cash equivalents of $39.0M, no debt; operations funded into 2025.
Revenue $1.7M from Nyxol license reimbursement (vs $0 prior year); net loss $5.8M ($0.28/sh) vs $6.6M ($0.35).
PDUFA date for Nyxol in RM set for Sept 28, 2023; approval triggers $10M milestone payment.
End-of-Phase 2 meeting with FDA for APX3330 in DR expected in 2H 2023.
Topline results for Nyxol in presbyopia (VEGA-2) expected in late 2023.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Opus Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue 1.7 million, net income -5.8 million, EPS -0.28.

Period: first quarter ended March 31, 2023
Revenue: 1.7 million
Net income: -5.8 million
EPS: -0.28
Result: reported results

Exact text from the filing

has no debt. Based on current projections, management believes the present cash on hand will be sufficient to fund operations into 2025. License and collaborations revenue was $1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022. Revenue during the first quarter of 2023 was derived from the

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Opus Genetics, Inc. reported first quarter ended March 31, 2023 results: revenue 1.7 million, net income -5.8 million, EPS -0.28.

Period: first quarter ended March 31, 2023
Revenue: 1.7 million
Net income: -5.8 million
EPS: -0.28
Result: reported results

Exact text from the filing

License and collaborations revenue was $1.7 million for the three months ended March 31, 2023. There was no revenue recorded in the three months ended March 31, 2022.

View on SEC.gov

31 earnings releases filed in the last 30 days. Browse all earnings releases →

Opus Genetics, Inc. filing history →

Source: SEC EDGAR

accession 0001140361-23-024502

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.